[Is CMV-hyperimmune serum prophylaxis after kidney transplantation always meaningful?].
CMV-infections are a common and dreadful complication in immunosuppressed patients after kidney transplantation. This randomized, controlled clinical study investigates the influence of CMV-hyperimmune serum (HIS)-prophylaxis on infection incidence and severity of illness with regard to the type of immunosuppression employed. Though the clinical manifestation of the disease is lowered by HIS in cyclosporin-treated patients, there is a higher infection incidence with increased severity in HIS-treated ATG/Imurek patients compared to the respective control.
D000961:Antilymphocyte Serum / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003524:Cyclosporins / Q000627:therapeutic use; D003587:Cytomegalovirus / Q000276:immunology; D003586:Cytomegalovirus Infections / Q000517:prevention & control*; D004660:Encephalitis / Q000382:microbiology; D006084:Graft Rejection; D006801:Humans; D007116:Immunization, Passive; D007165:Immunosuppression Therapy / Q000009:adverse effects; D016030:Kidney Transplantation
D000961:Antilymphocyte Serum; D003524:Cyclosporins
Ist die CMV-Hyperimmunserumprophylaxe nach Nierentransplantation immer sinnvoll?